Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc.

NEW YORK–(BUSINESS WIRE)– Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq Global
Market: CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR-T cells (UCART), has entered
into a supply and license agreement with Takara Bio Inc. for recombinant
human fibronectin fragment RetroNectin®.

Access to Takara Bio Inc.’s RetroNectin will secure Cellectis’
manufacturing processes and expand the Company’s UCART production
capabilities. Under the terms of the agreement, RetroNectin, which is
used for cell engineering, may be applied in the production of both R&D-
and GMP-grade Cellectis’ UCART product candidates.

Financial terms of the agreement are not disclosed.

“This agreement with Takara Bio will not only secure the manufacturing
of Cellectis’ robust product pipeline but also strengthen our key assets
and capabilities in the cell engineering space,” said Dr David Sourdive,
EVP Corporate Development at Cellectis. “The partnership ultimately
furthers our effort to provide universal CAR-Ts for immunotherapy
patients all over the world.”

“We are very grateful to provide RetroNectin for Cellectis’ UCAR T-cell
manufacturing process, which is one of the world’s most advanced program
in immunotherapy,” added Dr. Yoh Hamaoka, Senior Executive Officer of
Business Development at Takara Bio Inc. “We are pleased that RetroNectin
contributes to the development of the emerging gene and cell therapy.”

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering – based on its flagship TALEN^® products
and meganucleases and pioneering electroporation PulseAgile technology –
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it.
TALEN^® is a
registered trademark owned by the Cellectis Group.

Restronectin® is a registered trademark owned by Takara Bio Inc.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160321006185/en/